Gatralimab
- Generic Name
- Gatralimab
- Drug Type
- Biotech
- CAS Number
- 1826020-80-7
- Unique Ingredient Identifier
- 87MNT78TAZ
- Background
Gatralimab is under investigation in clinical trial NCT02389452 (Study of Safety and Efficacy of 6 Ml Synvisc-one (Hylan G-F 20) in Indian Patients With Symptomatic Osteoarthritis of Knee(s) After Initial and Repeat Treatment).
A Single Ascending Dose Study of GZ402668 in Patients With Progressive Multiple Sclerosis
Phase 1
Completed
- Conditions
- Progressive Multiple Sclerosis
- Interventions
- First Posted Date
- 2016-11-30
- Last Posted Date
- 2022-04-25
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 20
- Registration Number
- NCT02977533
- Locations
- 🇩🇪
Investigational Site Number 276001, Berlin, Germany
A First-in-human, Single Ascending Dose Study of GZ402668 in Patients With Progressive Multiple Sclerosis
Phase 1
Completed
- Conditions
- Progressive Multiple Sclerosis
- Interventions
- First Posted Date
- 2014-11-04
- Last Posted Date
- 2016-04-13
- Lead Sponsor
- Genzyme, a Sanofi Company
- Target Recruit Count
- 48
- Registration Number
- NCT02282826
- Locations
- 🇩🇪
Investigational Site Number 276001, Berlin, Germany
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath